EPIC-Spain: Olive Oil Linked to Lower Coronary Heart Disease Risk

This 10-year prospective cohort study from the European Prospective Investigation into Cancer and Nutrition (EPIC-Spain) tracked 40,142 Spanish adults to test whether higher olive oil intake was associated with fewer coronary heart disease events. Published in the British Journal of Nutrition, the analysis found that each 10 g/day increase in olive oil intake (per 2,000 kcal) was associated with a 7% lower risk of CHD overall, with stronger effects in never-smokers, low-alcohol consumers, and consumers of virgin olive oil specifically.

Why This Study Matters

Olive oil is well known for its cardioprotective properties in mechanistic and short-term clinical studies. But until this analysis, epidemiological data showing that olive oil consumption actually reduces incident coronary heart disease events in a population were limited. Most prior research came from case-control studies or focused on Mediterranean diet patterns as a whole, making it hard to isolate the contribution of olive oil itself.

EPIC-Spain was designed to fill that gap. It enrolled more than 40,000 adults from five regions of Spain between 1992 and 1996, captured baseline dietary intake using a validated dietary history method, and followed participants prospectively for incident cardiovascular events. By 2004, the cohort had accumulated more than 400,000 person-years of follow-up and 587 confirmed CHD events.

The result was a clear inverse association: higher olive oil intake was linked to lower CHD incidence, with the dose-response signal strengthening when the researchers excluded participants whose dietary reports were implausibly low or high. The cleanest signal emerged in virgin olive oil consumers, who showed a 14% reduction in CHD risk per 10 g/day increment.

How It Was Designed

The basics: 40,142 participants (38% male), aged 29 to 69 at recruitment, drawn from five EPIC-Spain centers (Asturias, Granada, Guipuzcoa, Murcia, and Navarra). All participants were free of CHD events at baseline. Median follow-up was 10.4 years.

Dietary intake was assessed at baseline using a computerized dietary history method -- a structured interview with trained dietitians that captured habitual intake over the past year, including the type of olive oil consumed (virgin vs. refined). This is a more detailed assessment than the food frequency questionnaires used in most other cohorts, which lets the researchers separate virgin olive oil from common olive oil and from total olive oil intake.

Cox proportional-hazards models were adjusted for age, sex, BMI, waist-to-hip ratio, smoking status, education, physical activity, alcohol intake, hypertension, diabetes, hyperlipidemia, and total energy intake. The analyses excluded dietary mis-reporters -- participants whose reported energy intake fell outside the plausible range -- in the primary analysis, on the grounds that implausibly low or high reports are likely to be wrong rather than reflective of unusual diets.

CHD events were ascertained from hospital discharge registries, population-based mortality registers, and direct medical record review, then validated by independent committees using ICD-10 codes for acute myocardial infarction (I21-I22) and unstable angina (I20.0).

What They Found

During 10.4 years of follow-up, 587 incident CHD events were recorded (79% in men). The hazard ratios for each 10 g/day increment in olive oil intake, and for the highest versus lowest quartile of intake, were:

Comparison	Hazard Ratio (95% CI)	Risk Reduction	What It Measures
+10 g/day olive oil	0.93 (0.87-1.00)	7% lower per 10 g	Incident CHD, full cohort excluding mis-reporters
Top vs. bottom quartile	0.78 (0.59-1.03)	22% lower (NS)	Incident CHD, highest vs. lowest intake
+10 g/day, never-smokers	0.89 (p=0.048)	11% lower per 10 g	CHD risk in never-smokers subgroup
+10 g/day, never/low drinkers	0.75 (p<0.001)	25% lower per 10 g	CHD risk in never/low-alcohol subgroup
+10 g/day virgin olive oil	0.86 (p=0.072)	14% lower per 10 g	CHD risk in virgin olive oil consumers

Green indicates a favorable direction. The primary continuous analysis reached statistical significance after excluding dietary mis-reporters. Subgroup analyses in never-smokers and never/low drinkers strengthened the signal.

Reading the Results

The findings group into three interpretive threads.

The main dose-response (7% lower CHD per 10 g/day). 10 grams of olive oil is roughly three-quarters of a tablespoon -- a moderate, achievable increase in daily intake. The 7% reduction is modest in magnitude but biologically coherent: olive oil delivers monounsaturated fat that improves LDL/HDL ratios, plus polyphenols that reduce oxidative stress and inflammation. The fact that the signal is graded across the range of intake -- not just an all-or-nothing effect at the high end -- supports a causal interpretation.

The subgroup signal in never-smokers and low-alcohol consumers (11% and 25% lower per 10 g/day). Smoking and heavy alcohol intake are powerful drivers of CHD risk that can overwhelm dietary effects. When the researchers restricted the analysis to people whose CHD risk wasn't dominated by those exposures, the olive oil association strengthened considerably. The 25% reduction per 10 g/day in never/low-drinkers is one of the largest dose-response signals reported in the EPIC literature.

The virgin olive oil specificity (14% lower per 10 g/day). EPIC-Spain is one of the few cohorts that distinguishes between virgin and refined olive oil. Virgin olive oil contains substantially higher concentrations of polyphenols -- hydroxytyrosol, oleuropein, oleocanthal -- because the refining process strips most of them out. The fact that the inverse association is stronger for virgin olive oil specifically is consistent with the polyphenol fraction driving at least part of the cardioprotective effect.

What Didn't Change

The top-quartile vs. bottom-quartile comparison did not reach conventional statistical significance (HR 0.78; 95% CI 0.59-1.03). The point estimate is large and in the expected direction, but the confidence interval crosses 1.0. This is because the highest-intake group already consumes substantial olive oil, and the lowest-intake group still consumes some -- the contrast in absolute intake is smaller than in non-Mediterranean cohorts. The continuous analysis (per 10 g/day) is the more informative model for this dataset.

The study is observational, not interventional. It cannot prove that consuming more olive oil causes lower CHD risk. The 27-covariate adjustment reduces but does not eliminate the possibility of residual confounding by overall diet quality, socioeconomic factors, or health-conscious behaviors.

Broader Context

The EPIC-Spain CHD findings are consistent with the broader epidemiological and trial literature. PREDIMED -- conducted in part by the same investigators working with overlapping infrastructure -- reported a 30% reduction in major cardiovascular events with a Mediterranean diet supplemented with extra virgin olive oil, in a randomized framework. The Harvard pooled cohort (Guasch-Ferre et al., 2022) reported a 19% reduction in cardiovascular mortality with the highest olive oil intake category in a non-Mediterranean U.S. population.

The 2011 European Food Safety Authority opinion (Regulation 432/2012) authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage at a daily intake of 5 mg of hydroxytyrosol and its derivatives. EPIC-Spain's virgin-olive-oil subgroup finding -- a 14% reduction per 10 g/day -- aligns with the polyphenol-specific mechanism EFSA recognized.

What this cohort adds is a population-level, dose-response signal: across more than 400,000 person-years in a Mediterranean population, more olive oil meant fewer heart attacks.

Related Research

Continue exploring olive oil and polyphenol science:

• EPIC-Spain: Higher Olive Oil Intake Linked to 26% Lower Mortality
• EPICOR Italian Women: Olive Oil & Leafy Vegetables Linked to 44% Lower CHD Risk
• Italian Cohort: Olive Oil Linked to Lower Cancer, CV and All-Cause Mortality

Source: View the original study on PubMed

Olivea's Dosage

EPIC-Spain identified a 7% reduction in CHD risk per 10 g/day increment in olive oil intake, with the strongest effect among virgin olive oil consumers. A single tablespoon of Olivea extra virgin olive oil delivers approximately 14 grams. Each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving in an EVOO matrix; our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.